Bladder Cancer VA Rating

Bladder cancer is one of the cleaner ratings in the VA schedule while it is active and one of the more contested once it is not. Under 38 CFR § 4.115b, diagnostic code 7528 assigns a flat 100 percent evaluation for a malignant neoplasm of the genitourinary system. There are no intermediate tiers during the active phase. Six months after treatment ends, a mandatory VA exam decides whether the cancer is still there. If it is not, the rating converts to the residuals, either voiding dysfunction or renal dysfunction under 38 CFR § 4.115a, whichever is predominant.

Service connection is often the easier half, because bladder cancer sits inside four presumptions: Agent Orange under 38 U.S.C. § 1116, Camp Lejeune, radiation-risk activity, and the January 2025 rule for Gulf War and post-9/11 service at 38 CFR § 3.320a. This page covers the 100 percent rule, the six-month exam and the notice that protects you on the way down, the residual ratings for bladder cancer in remission, each presumption, and why VA denies these claims.

TL;DR

• Bladder cancer is rated under 38 CFR § 4.115b, DC 7528 (malignant neoplasms of the genitourinary system), at a flat 100 percent during active disease and treatment.
• After treatment ends, the 100 percent continues until a mandatory VA exam at the six-month mark. Ongoing intravesical therapy such as BCG can mean treatment has not ended.
• If there is no local recurrence and no metastasis, the cancer is rated on its residuals under § 4.115a, as voiding dysfunction or renal dysfunction, whichever is predominant. Leakage that needs pads rates 20, 40 or 60 percent; a urinary diversion with a stoma appliance rates 60 percent.
• Any change after the exam follows the notice procedure in 38 CFR § 3.105(e): a proposed rating, 60 days to send evidence, and 30 days to ask for a hearing.
• Bladder cancer is presumptive for covered herbicide service under 38 U.S.C. § 1116(a)(2)(J), for qualifying Camp Lejeune service under 38 CFR §§ 3.307(a)(7) and 3.309(f), for radiation-exposed veterans under § 3.309(d), and since January 2, 2025 for covered Gulf War and post-9/11 veterans under 38 CFR § 3.320a.
• Across 1,485 decided Board rulings on bladder cancer from 2021 to 2026, 40.7% were granted, 27.6% denied and 31.7% remanded. A ruling is one issue the Board decided in one decision; one decision often rules on several issues. Granted is the most common outcome. The grant rate is 16.0 points above the Board-wide 24.7%, and the remand share is 13.6 points below the Board-wide 45.3%.

Bladder cancer VA rating under diagnostic code 7528

The entire genitourinary cancer family sits under DC 7528 in 38 CFR § 4.115b. The code assigns 100 percent and attaches a note, and almost every dispute turns on a phrase in that note.

7528 Malignant neoplasms of the genitourinary system: 100%

Following the cessation of surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure, the rating of 100 percent shall continue with a mandatory VA examination at the expiration of six months. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local reoccurrence or metastasis, rate on residuals as voiding dysfunction or renal dysfunction, whichever is predominant.

The 100 percent is automatic for the active phase; there is no "moderate" or "severe" bladder cancer tier. A confirmed bladder cancer that is being treated rates 100 percent, which pays $3,938.58 a month for a veteran alone at the 2026 rates. The rating also does not end on its own. It "shall continue" until the mandatory examination six months after treatment stops, and that clock starts when the last therapeutic procedure ends, not at diagnosis, which matters when treatment is staged or a recurrence restarts it.

When the 100 percent ends: the six-month exam

The mandatory exam answers whether the cancer is still present: is there local recurrence, is there metastasis. If the cancer is active or has come back, the 100 percent continues. If the exam shows no recurrence and no metastasis, the rating converts to the residuals.

Ongoing treatment counts. BCG instilled into the bladder after the tumor is removed is the mainstay first-line treatment for high-risk non-muscle-invasive bladder cancer, and it can continue as maintenance therapy (PMID 33262624). In a March 2025 decision, the Board restored a 100 percent rating that VA had cut while the veteran was still receiving immunotherapy, finding that treatment had not ended and the cancer was not in remission (Citation Nr. A25020622). In a January 2025 decision, the Board restored 100 percent where the record showed the cancer remained active, including a BCG-refractory tumor (Citation Nr. A25003368).

Recurrence restarts the 100 percent. In a May 2025 decision, the Board assigned 100 percent again from the date a surveillance cystoscopy found a new tumor (Citation Nr. A25044827).

The notice rule. Any change after the exam follows 38 CFR § 3.105(e). When the change would lower your payments, VA has to issue a proposed rating with its reasons, give you 60 days to send evidence, and offer a predetermination hearing if you ask within 30 days of the notice. If you ask in time, payments continue at the old level until VA decides. The lower rating takes effect at the end of the month in which 60 days from the notice of the final action run out.

The Board does not treat the end of the DC 7528 100 percent as an ordinary rating reduction, because the code sets its own end point; the improvement rules in 38 CFR §§ 3.343 and 3.344 do not apply (Foster v. McDonough, 34 Vet. App. 338 (2021), as applied in Citation Nr. A25003368). The fight is over whether treatment really ended, whether the cancer is really inactive, and whether VA gave the § 3.105(e) notice.

VA rating for bladder cancer in remission: voiding or renal residuals

Once the cancer is in remission, the rating runs on residuals under § 4.115a, as "voiding dysfunction or renal dysfunction, whichever is predominant." Those are two different rating systems, and the rater is supposed to pick the one that most disables you, not the one that is easiest to document. In the 2025 Board decisions on bladder cancer I read, the residuals were usually rated as voiding dysfunction.

Voiding dysfunction is rated on whichever particular problem you have: urine leakage, urinary frequency, or obstructed voiding.

• Leakage, which includes post-surgical urinary diversion, urinary incontinence, and stress incontinence: 60 percent when it requires an appliance or absorbent materials changed more than 4 times a day, 40 percent for changes 2 to 4 times a day, and 20 percent for changes less than 2 times a day.
• Frequency: 40 percent for a daytime voiding interval under one hour or waking to void five or more times a night, 20 percent for an interval of one to two hours or three to four times a night, and 10 percent for an interval of two to three hours or two times a night.
• Obstructed voiding: 30 percent for urinary retention requiring intermittent or continuous catheterization, and 10 percent for marked obstructive symptoms with findings such as post-void residuals over 150 cc.

At the 2026 rates for a veteran alone, 20 percent pays $356.66 a month, 40 percent $795.84 and 60 percent $1,435.02. Intravesical BCG commonly causes frequent urination and other lower urinary tract symptoms (PMID 33262624), which is why the frequency criteria often apply. In a January 2025 decision, the Board assigned 20 percent for bladder cancer residuals with a daytime voiding interval of one to two hours and three to four nighttime voids (Citation Nr. A25000271). After a radical cystectomy with a urinary diversion and a stoma, the leakage criteria's appliance language applies: in a March 2025 decision, the Board assigned 60 percent for post-surgical urinary diversion requiring an appliance (Citation Nr. A25027929). A residual picture with no voiding or renal findings rates 0 percent.

Renal dysfunction applies when kidney function is the predominant residual. It is rated on glomerular filtration rate (GFR or eGFR) sustained for at least 3 consecutive months in the past 12: 30 percent for 45 to 59, 60 percent for 30 to 44, 80 percent for 15 to 29, and 100 percent for under 15, regular routine dialysis, or eligibility for a kidney transplant. Kidney function can fall after radical cystectomy: in a Danish study of 670 patients, the share with an eGFR under 45 rose from 8.9 percent before surgery to 19 percent five years after (PMID 34838541).

The two systems do not produce the same number from the same clinical picture. A veteran with heavy incontinence can rate high under voiding dysfunction with normal labs that would rate low under renal dysfunction. When a decision rates a clearly incontinent veteran under the renal criteria, that is a misapplication of "whichever is predominant," and it is appealable. Erectile dysfunction after treatment is a separate question; see erectile dysfunction.

Bladder cancer and Agent Orange

Bladder cancer is a presumptive Agent Orange disease by statute. 38 U.S.C. § 1116(a)(2)(J) lists bladder cancer for a veteran with covered herbicide service. Congress added it through the FY2021 National Defense Authorization Act (Pub. L. 116-283, § 9109, signed January 1, 2021), along with parkinsonism and hypothyroidism, not through the PACT Act. The herbicide table in 38 CFR § 3.309(e) still does not list bladder cancer, so § 1116 is the controlling citation rather than a claim that the regulatory table itself lists it.

Covered service under § 1116(d) includes the Republic of Vietnam from January 9, 1962 to May 7, 1975, U.S. or Royal Thai bases in Thailand from January 9, 1962 to June 30, 1976, and listed places and periods in Laos, Cambodia, Guam, American Samoa, and Johnston Atoll. Separate sections cover service offshore of Vietnam (§ 1116A) and in or near the Korean DMZ (§ 1116B). With covered service and a confirmed diagnosis, you do not need a nexus opinion. The presumption covers bladder cancer, not benign bladder conditions, but bladder dysfunction left after cancer treatment is rated as a residual of the service-connected cancer.

Other bladder cancer presumptions: Camp Lejeune, § 3.320a and radiation

Camp Lejeune. 38 CFR §§ 3.307(a)(7) and 3.309(f) make bladder cancer presumptive for veterans, former reservists, and former National Guard members with at least 30 days, consecutive or not, at Camp Lejeune or Marine Corps Air Station New River between August 1, 1953 and December 31, 1987.

Gulf War and post-9/11 service, 38 CFR § 3.320a. VA added this presumption through an interim final rule effective January 2, 2025 (90 FR 23), issued under its PACT Act authority. It covers urinary bladder cancer, including overlapping sites of the bladder, and ureter cancer, including the ureteric orifice and urachus. A covered veteran is one assigned to a duty station in the Southwest Asia theater of operations or Somalia on or after August 2, 1990, or in Afghanistan, Djibouti, Egypt, Jordan, Lebanon, Syria, Yemen, or Uzbekistan on or after September 11, 2001, including the airspace above. The original 2022 list in 38 U.S.C. § 1120 did not itself name bladder cancer; VA added it in 2025 using its authority to add presumptions. In a March 2025 decision, the Board granted bladder cancer for a covered veteran with Gulf War service under § 3.320a (Citation Nr. A25026993).

Radiation. Cancer of the urinary tract, which the regulation defines to include the urinary bladder, is on the list at 38 CFR § 3.309(d) for radiation-exposed veterans. In a February 2025 decision, the Board granted bladder cancer after finding the evidence of radiation exposure in approximate balance (Citation Nr. A25009516).

Each presumption needs the service proof as well as the diagnosis. Unit records, orders, and dates that place you at the covered location, plus the biopsy or surgical pathology report, are what turn a contested direct claim into a presumptive one. The secondary conditions tool can help map exposure-driven and downstream conditions that travel with a genitourinary cancer.

The bladder cancer C&P exam

The conversion exam and any later residual exam follow the genitourinary DBQ. Which residual path applies depends on what the examiner documents.

For the cancer-status question, the examiner has to confirm whether there is active disease, local recurrence, or metastasis, and identify the date the last treatment ended, including any maintenance intravesical therapy. That date sets the six-month clock.

For the voiding-dysfunction path, the examiner should record the following.

• Urine leakage and the type of management: the number of absorbent pad changes per day, and whether an appliance is required, including a urostomy appliance after urinary diversion
• Urinary frequency: daytime voiding interval and nighttime awakenings to void
• Obstructed voiding markers: hesitancy, stream strength, post-void residual volume, and any need for catheterization or dilatation
• Any urinary tract infection history and recurrent treatment

For the renal-dysfunction path, the examiner should document GFR or eGFR results over time (the criteria look for at least 3 consecutive months in the past 12), the albumin/creatinine ratio, any structural kidney abnormalities, dialysis status, and kidney transplant eligibility.

When the exam confirms remission and stops, the rater has nothing to place you in a voiding or renal tier, and the converted rating lands below your actual symptoms. When the Board sent bladder cancer claims back, the most common reason was that VA still had records to get, followed by an inadequate VA exam or opinion; the Board section below shows each remand reason.

Why VA denies bladder cancer claims

When the Board denied bladder cancer service connection, the part it most often found missing was a link to service, usually alongside a missing in-service event or exposure; the Board section below shows how often each part failed, and how claims went by what the appeal asked for, including higher ratings and earlier effective dates. These are the gaps that repeat.

Service outside every presumption. A veteran whose service does not match the herbicide locations and dates, the Camp Lejeune window, a radiation-risk activity, or the § 3.320a duty stations has no presumption, and a direct claim needs a medical opinion that links the cancer to something in service. Two 2025 denials turned on service dates or places that § 3.320a does not cover (Citation Nr. A25014227, A25021762).

Exposure proof missing even when the pathway exists. The diagnosis is in the file, but the unit records, orders, or dates that activate the presumption are not.

Treatment-end date not pinned down. When the record is vague about when the last procedure ended, or when intravesical therapy was given in cycles, the conversion timing gets muddled. A clear treatment-end date in the oncology record protects the full 100 percent.

Residual exam developed for the cancer, not the residuals. The exam records "no recurrence" but never counts pad changes, voiding intervals, or obstructed-voiding markers.

Wrong fork applied. A veteran with significant incontinence is rated on normal kidney labs, or genuine renal involvement is squeezed into voiding criteria.

§ 3.105(e) notice skipped or rushed. When VA ends the 100 percent without a proposal, the 60-day evidence window, and the hearing offer, the reduction is void regardless of the medical picture.

Across 1,485 decided Board rulings on bladder cancer, 40.7% were granted, 27.6% denied and 31.7% remanded. The Board section below also shows how claims went when the Board relied on a favorable medical opinion or weighed none, and how direct and presumptive claims fared. Those are associations, not proof that any one piece of evidence caused the result.

Questions veterans ask about bladder cancer

What is the VA rating for bladder cancer?

Bladder cancer rates 100 percent under DC 7528 while it is active and during treatment, and the 100 percent continues until a mandatory exam six months after treatment ends. After that, it is rated on its residuals as voiding or renal dysfunction, from 0 up to 100 percent.

What is the VA disability rating for bladder cancer in remission?

In remission, bladder cancer is rated on its residuals. Leakage needing pads rates 20 to 60 percent, urinary frequency 10 to 40 percent, catheter-dependent retention 30 percent, and kidney decline by GFR, with 0 percent when there are no residual findings.

Is bladder cancer on the Agent Orange presumptive list?

Yes. 38 U.S.C. § 1116(a)(2)(J) has listed bladder cancer since January 1, 2021, so a veteran with covered herbicide service and a confirmed diagnosis does not need a nexus opinion. The table in 38 CFR § 3.309(e) has not been updated to show it, but the statute controls.

Does BCG treatment keep my 100 percent bladder cancer rating?

It can. The 100 percent continues until six months after treatment ends, and the Board has restored 100 percent where VA cut the rating while the veteran was still receiving immunotherapy.

What is VA diagnostic code 7528?

DC 7528 is the code for malignant neoplasms of the genitourinary system, which covers bladder, prostate, kidney, and other urinary and genital cancers. It assigns 100 percent during treatment and then rates the residuals as voiding or renal dysfunction.

Is bladder cancer presumptive for Gulf War and post-9/11 veterans?

Yes, since January 2, 2025. 38 CFR § 3.320a presumes service connection for urinary bladder and ureter cancer for veterans assigned to a duty station in the Southwest Asia theater or Somalia on or after August 2, 1990, or in eight listed countries on or after September 11, 2001.

Bottom Line

Bladder cancer is two ratings wearing one diagnostic code. While the cancer is active and under treatment, DC 7528 pays a flat 100 percent, and ongoing therapy such as BCG can keep that rating in place. Six months after treatment ends, a mandatory exam decides whether the cancer is gone, and if it is, the rating drops to a residual evaluation on voiding or renal dysfunction, whichever is predominant, with § 3.105(e) notice required on the way down. Service connection often runs through a presumption: covered herbicide service under 38 U.S.C. § 1116, Camp Lejeune, radiation-risk activity, or the 2025 § 3.320a rule for Gulf War and post-9/11 service. The cases that hold their value document the treatment-end date, quantify the residual symptoms, apply the correct fork, and keep the exposure proof next to the pathology.

Related Conditions

Bladder cancer claims commonly connect to other genitourinary pages because the residual rating systems and the exposure pathways overlap. See prostate cancer and the prostate page, which run on the same DC 7528 active-cancer rule and the same voiding-versus-renal residual fork. The bladder page covers non-malignant bladder conditions rated directly on voiding dysfunction, and kidney disease covers the renal-dysfunction side of § 4.115a in more depth. Veterans with a genitourinary cancer should also review the secondary conditions tool to map exposure-driven and downstream conditions.

Methodology and Limitations

• Data source: Rating criteria quoted from 38 CFR § 4.115b, DC 7528, and the residual criteria at § 4.115a, checked against the eCFR text in October 2026. Reduction procedure from 38 CFR § 3.105(e) and (i), with Foster v. McDonough on time-limited 100 percent ratings. Toxic-exposure pathways reflect 38 U.S.C. § 1116 (herbicide exposure, with the § 9109 amendment history), 38 CFR §§ 3.307(a)(7) and 3.309(f) (Camp Lejeune water), 38 CFR § 3.309(d) (radiation-exposed veterans), and 38 CFR § 3.320a (covered Gulf War and post-9/11 service, 90 FR 23, still an interim final rule as of October 2026). Board decisions cited by citation number come from the 2025 Board decision files. Medical statements cite PubMed abstracts by PMID. Outcome figures from Claim Raven's read of every Board decision from 2021 to 2026 that it holds: 511,036 decisions containing 1,378,030 rulings.
• Sample size: 1,744 Board rulings on bladder cancer, 1,485 of them decided. Of the decided rulings, 604 were granted (40.7%), 410 denied (27.6%) and 471 remanded (31.7%). The Board section on this page breaks these down by denial reason, remand reason, appeal type, medical opinion, claim theory and era; those figures are computed from the data, not typed here. The read does not code the residual path (voiding or renal) or rating tiers.
• Classification approach: Diagnostic code and residual definitions drawn from the regulatory text. The conversion and reduction analysis follows the DC 7528 note and § 3.105(e). Exposure-pathway descriptions follow the statutory and regulatory presumption lists. I compare the grant and remand shares with the Board-wide figures rather than asserting a causal claim about why each case resolved as it did.
• Limitations:
• Application of the conversion timing varies where treatment is staged, where maintenance intravesical therapy continues, or where a recurrence restarts treatment. The Board decisions cited here are examples, not a count of how often each outcome occurs.
• Whether the predominant residual is voiding or renal dysfunction is fact-specific and depends on the quality of the exam.
• Presumptive status depends on meeting the specific service, location, and timeframe criteria for the relevant exposure framework. Not every veteran with bladder cancer qualifies for a presumptive pathway.
• Selection bias: BVA-level patterns reflect cases that appealed. Most bladder cancer claims resolve at the RO level and are not in any BVA dataset. The comparatively high grant share for this condition should be read in that light.
• Compensation amounts reflect the 2026 VA rate tables (effective December 1, 2025) for a single veteran with no dependents and change annually with COLA.
• These observations reflect patterns from the regulatory text and BVA decisions. They are not predictions of individual outcomes.